Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID).
Agafina A, Aguiar VC, Rossovskaya M, Fartoukh MS, Hajjar LA, Thiéry G, Timsit JF, Gordeev I, Protsenko D, Carbone J, Pellegrini R, Stadnik CMB, Avdeev S, Ferrer M, Heinz CC, Häder T, Langohr P, Bobenhausen I, Schüttrumpf J, Staus A, Ruehle M, Weissmüller S, Wartenburg-Demand A, Torres A.
Agafina A, et al. Among authors: carbone j.
Eur J Med Res. 2024 Aug 13;29(1):418. doi: 10.1186/s40001-024-02008-x.
Eur J Med Res. 2024.
PMID: 39138518
Free PMC article.
Clinical Trial.